BRIEF — Sanofi next to agree Evotec deal

French drugmaker Sanofi is the latest pharma major to announce that it is working with German biotech Evotec in drug discovery.

Their collaboration, called LAB031, is designed to accelerate drug discovery across multiple therapeutic areas. It is one of Evotec’s BRIDGE initiatives, which are public-private partnerships bringing core strengths of academia, biotech and venture capital with strong links into pharma, under one roof.

Shiv Krishnan, head of technology platforms, global business development and licensing at Sanofi, said: “We are pleased to expand our relationship with Evotec and establish LAB031.

"Sanofi is focused on identifying the best resources available in order to translate academic innovation into clinical assets.”